Determine the effect of multiple doses of AZD7325, CYP Study - CYP

Study identifier:D1140C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I open-labeled, fixed sequence study to determine the effect of multiple doses of AZD7325 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2)

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7325, Midazolam, Caffeine

Sex

Male

Actual enrollment

24

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria